The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy
Table 6
(a) The comparison of the selected parameters of oxidative stress in serum in men
Group
De novo RRMS
INF
FG
NT
Control
N
8
9
17
6
9
LHP (μmol/l)
20.59 ± 13.87
18.57 ± 25.81
4.10 ± 3.72
9.29 ± 7.28
0.70 ± 0.51
0.001
MDA (μmol/l)
5.73 ± 1.92
5.12 ± 3.43
3.64 ± 0.99
4.60 ± 1.79
2.43 ± 0.24
0.003
TOS (μmol/l)
32.99 ± 21.51
31.24 ± 41.71
8.92 ± 7.05
21.48 ± 18.95
2.27 ± 0.98
0.002
(b) Post hoc analysis for men
Parameter
LHP
Group
FG
NT
De novo RRMS
NS
INF
NS
NS
Control
NS
NS
(c) Post hoc analysis for men
Parameter
LHP
MDA
TOS
Group
INF
Control
INF
Control
INF
Control
De novo RRMS
NS
NS
NS
Control
x
x
NS
x
De novo RRMS: patients with a newly diagnosed relapsing-remitting multiple sclerosis; RRMS INF: RRMS patients treated with interferon beta; FG: RRMS patients treated with fingolimod; NT: RRMS patients treated with natalizumab; LHP: lipid hydroxyperoxides; NA: nonapplicable; statistical significance for .
